In fact, the dual anti-Ang2/VEGFRs therapy has been shown to enhance the length of the window of vessel normalization in vivo, thus achieving survival improvement and tumour burden reduction upon dual VEGFR2-Ang2 inhibition [193]. This evidence concerns the gene ANGPT2 and neoplasm.